Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-09-04
2007-09-04
Mertz, Prema (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C424S001370, C424S001410
Reexamination Certificate
active
08494093
ABSTRACT:
The present invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to proteins or polypeptides referred to herein as isolated and/or recombinant human eotaxin, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, which are useful in in vitro methods, diagnostic and/or therapeutic applications.Also provided are methods of use of the proteins of the present invention, for example in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used in assays to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin function. Agents which inhibit or promote eotaxin function can be administered to an individual, providing a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections.
REFERENCES:
patent: 5993814 (1999-11-01), Williams et al.
patent: 6001649 (1999-12-01), Caput et al.
patent: 6031080 (2000-02-01), Williams et al.
patent: 6403782 (2002-06-01), Luster et al.
patent: 6780973 (2004-08-01), Luster et al.
patent: WO90/07863 (1990-07-01), None
patent: WO95/07985 (1995-03-01), None
patent: WO96/25497 (1996-08-01), None
patent: WO97/12914 (1997-04-01), None
patent: WO97/46683 (1997-12-01), None
Cunningham et al. (1989) Science, vol. 244, pp. 1081-1085.
George et al. (1988) Micromolecular Sequencings & Synthesis, Ch. 12, pp. 127-149, Alan R. Liss, Inc. New York.
Mikayama et al. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060, 1993.
Voet et al. Biochemistry John Wiley & Sons, Inc., pp. 126-128 and 228-234.
Miller, M.D., et al., “Biology and Biochemistry of the Chemokines: A Family of Chemotactic and Inflammatory Cytokines”,Critical Reviews in Immunology,12(1,2): 17-46 (1992).
Baggiolini, M. and C.A. Dahinden, “CC chemokines in allergic inflammation”,Immunology Today,15(3): 127-133 (1994).
Jose, P.J., et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation”,J. Exp. Med.,179: 881-887 (1994).
Jose, P.J., et al., “Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs”,Biochemical and Biophysical Research Communications,205(1): 788-794 (1994).
Rothenberg, M.E., et al., “Constitutive and Allergen-induced Expression of Eotaxin mRNA in the Guinea Pig Lung”,J. Exp. Med.,181: 1211-1216 (1995).
Tepper, R.I., et al., “Murine Interleukin-4 Displays Potent Anti-Tumor Activity in Vivo”,Cell,57: 503-512 (1989).
Kameyoshi, Y., et al., “Cytokine RANTES Released by Thrombin-stimulated Platelets Is a Potent Attractant for Human Eosinophils”,J. Exp. Med.,176: 587-592 (1992).
Griffiths-Johnson, D.A., et al., “The Chemokine, Eotaxin, Activates Guinea-Pig Eosinophils in vitro and Causes Their Accumulation into the Lung in vivo”,Biochemical and Biophysical Research Communications,197(3): 1167-1172 (1993).
Rothenberg, M.E., et al., “Murine Eotaxin: An Eosinophil Chemoattractant Inducible in Endothelial Cells and in Interleukin 4-induced Tumor Suppression”,Proc. Natl. Acad. Sci. USA,92: 8960-8964 (1995).
Kitaura, M., et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3”,The Journal of Biological Chemistry,271(13): 7725-7730 (1996).
Rot, A., et al., “RANTES and Macrophage Inflammatory Protein 1α Induce the Migration and Activation of Normal Human Eosinophil Granulocytes”,J. Exp. Med. 176(6):1489-1495 (1992).
Schröder, J.-M., et al., “Platelets Secrete an Eosinophil-Chemotactic Cytokine Which is a Member of the C-C-Chemokine Family”,Advances in Exp. Med. and Biology 351:119-128 (1993).
Wardlaw, A.J., et al., “Platelet-Activating Factor, A Potent Chemotactic and Chemokinetic Factor for Human Eosinophils”,J. Clin. Invest. 78:1701-1706 (1986).
Ponath, P.D., et al., “Cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Properties Suggest a Mechanism for the Selective Recruitment of Eosinophils”,J. Clin. Invest. 97(3):604-612 (1996).
Garcia-Zepeda, E.A., et al., “Human Eotaxin is a Specific Chemoattractant for Eosinophil Cells and Provides a New Mechanism to Explain Tissue Eosinophilia”,Nature Medicine 2(4):449-456 (1996).
Mackay Charles
Newman Walter
Ponath Paul D.
Qin Shixin
Ringler Douglas J.
Hamilton Brook Smith & Reynolds P.C.
Mertz Prema
Millennium Pharmaceuticals Inc.
LandOfFree
Human chemotactic cytokine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human chemotactic cytokine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human chemotactic cytokine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767574